Neuroprotective activity of sub-anesthetic ketamine in a preclinical model of Parkinson's disease is not blocked by antagonizing brain-derived neurotrophic factor signaling
Carolyn J. Stopera, Mitchell J. Bartlett, Kelsey Bernard, Rachel Conklin, Sansita Singh, Jennifer Beischel Frye, Lalitha Madhavan, Kristian P. Doyle, Scott J. Sherman, Kathy Steece‐Collier, Torsten Falk
This study shows that low-dose ketamine protects against Parkinson's-like motor deficits in rats without relying on BDNF-TrkB signaling.
bioRxiv · Oct 29, 2026 · PreprintNeuroscience